Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
December 16, 2025
Approximately 5 minutes
Mandatory Post-Market Surveillance (PMS) for Medical Devices in Indonesia
Mandatory Post-Market Surveillance (PMS) for Medical Devices in Indonesia
Post-Market Surveillance (PMS) is a mandatory and critical component of medical device compliance for all manufacturers selling in Indonesia. The Indonesian Ministry of Health (MoH) has harmonized its PMS expectations with the ASEAN guidelines on Post Market Vigilance (Annex 5 of the AMDD), focusing on traceability, complaint handling, and adverse event reporting.
Reporting Systems and Compliance Responsibility
All communication and reporting related to PMS are centralized through two online platforms managed by the MoH:
- E-Report System: Used for submitting records of importation and distribution. Maintaining accurate records is essential for the traceability of medical devices within the Indonesian market.
- E-Watch System: Used for mandatory reporting of Adverse Events (AEs), complaint records, and Field Safety Corrective Actions (FSCA).
The local medical device dealer (importer/distributor/License Holder) is legally responsible for maintaining complaint records, establishing investigation procedures, and mandatory reporting to the MoH.
Adverse Event (AE) Reporting Timelines
The timely reporting of Adverse Events is paramount. The required reporting timeline to the MoH depends on the severity of the event:
| Event Severity | Reporting Timeline |
|---|---|
| Serious Threat to Public Health | Not later than 48 hours |
| Led to Death or Serious Deterioration in Health | Not later than 10 days |
| Recurrence Might Lead to Death or Serious Deterioration | Not later than 30 days |
The objective of AE reporting is to improve public health and safety by disseminating information that can prevent the recurrence of safety issues.
Field Safety Corrective Action (FSCA)
An FSCA is required when the product owner must take action (including product recall) to eliminate or reduce the risk associated with identified hazards.
- Scope: An FSCA applies to any medical device that has already been distributed, even if it has been withdrawn from the market but could still be in use (e.g., implants).
- Responsibility: The product owner, physical manufacturer, authorized representative(s), importer, and/or authorized distributor(s) in Indonesia are collectively responsible for performing and completing the FSCA within the country. FSCA does not apply to purely commercial actions like product upgrades without a safety risk.
Ask Anything
We'll follow up with you personally.
Related Articles
Approximately 5 minutes
Navigating Medical Device Registration in Indonesia: MoH Approval, CSDT, and Local Agents
Medical device registration in Indonesia, overseen by the MoH, requires a **local, licensed Sole Importer** to hold the non-transferable product license (NIE). The process utilizes the **ASEAN CSDT** and classifies devices into four risk classes (A-D), with review times ranging from 15 to 45 days, and mandates **ISO 13485** certification and **Reference Country** approval.
Approximately 5 minutes
In Vitro Diagnostics (IVD) Product Registration in Indonesia: Classification and Local Requirements
IVD device registration in Indonesia is managed by the Ministry of Health (MoH) and requires a **local, licensed distributor** to hold the non-transferable product license. The process follows **GHTF/AMDD** guidelines for risk-based classification (Class A-D) and mandates both **Reference Country approval** and specific testing for high-risk devices like HIV reagents, with review timelines ranging from 30 to 90 days.
Approximately 5 minutes
Mandatory Local Labeling for Medical Devices in Indonesia: MoH Requirements
Medical device labeling in Indonesia is strictly governed by the Ministry of Health (MoH) and requires key information, particularly the **Intended Use** and **Instructions For Use (IFU)**, to be translated into **Bahasa Indonesian**. Labels, which include the marketing license number (**AKL Number**), can be affixed by the local license holder **after** customs clearance, ensuring compliance for domestic distribution.
Approximately 5 minutes
Medical Device License Amendment in Indonesia: Changes, Renewal, and Halal Compliance
Maintaining a medical device license (NIE) in Indonesia requires amendments for minor changes, renewal every five years, and adherence to evolving **Halal certification** requirements. Minor changes, such as labeling or packaging size, require an amendment application (IDR 1,000,000) that is typically approved within **3 months**, whereas all other significant changes necessitate a **new registration submission**.
Approximately 5 minutes
Role of the Ministry of Health (MoH) in Medical Device Regulation
The Indonesian Ministry of Health (MoH) is the central regulatory body for medical devices, responsible for **pre- and post-market evaluation, standardization, and GMP certification**. The MoH utilizes the **Government e-Catalogue** for public procurement transparency and enforces **Good Method of Distribution of Medical Devices (CDAKB)**, while aligning its risk classification system (Classes A-D) with the **ASEAN Medical Devices Directive (AMDD)**.